Key result
Ticagrelor shows no benefit over aspirin for preventing vein graft occlusion 2 years after CABG.
Why the study?
Ticagrelor did not improve vein graft patency 1 year after CABG in the TARGET trial, but its long-term impact on graft patency remained unknown.
Does ticagrelor reduce vein graft occlusion at 2 years in post-CABG patients compared to aspirin?
Population
156 CABG patients who agreed to a second year of double-blind study drug administration
Comparison
Ticagrelor 90 mg twice daily vs aspirin 81 mg
Design
Observational analysis from a multicenter randomized double-blind trial
Follow-up
2 years
Authors
Loading...
Ticagrelor was not associated with reduced vein graft occlusion post-CABG; leaves open whether RCTs would demonstrate benefit over aspirin.
Observational (n=156)
Double-blind
Randomized
Yes
Does ticagrelor reduce vein graft occlusion at 2 years in post-CABG patients compared to aspirin?
Absolute Event Rate: 13.2% vs 15.7%
p-value: p=0.71
Ticagrelor does not significantly improve vein graft patency at 2 years post-CABG compared to standard aspirin therapy.
Kulik et al. (2022) conducted an observational in Coronary bypass surgery (CABG) (n=156). Ticagrelor vs. Aspirin 81 mg was evaluated on Vein graft occlusion at 2 years (p=0.71). Ticagrelor did not significantly reduce vein graft occlusion at 2 years compared to aspirin following coronary bypass surgery (13.2% vs. 15.7%, p=0.71).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: